BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and…